Inhibition of Ceramide De Novo Synthesis with Myriocin Affects Lipid Metabolism in the Liver of Rats with Streptozotocin-Induced Type 1 Diabetes

Table 1

Effect of streptozotocin-induced diabetes and myriocin treatment (for 7 days) on body weight, fasting serum glucose, insulin, and FFA levels.

	C	M	D	D + M
Body weight (g)	305,8±18,00	246,0±16,93^∗	215,2±10,85^∗	188,2±12,09^∗†
Glucose level (mg/dL)	102,8±5,93	92,8±6,34	536,0±16,26^∗	254,6±24,80^∗†
Insulin level (µU/mL)	4,5±0,81	4,8±0,64	nd	nd
FFA level (µmol/L)	88,6±10,48	95,8±8,89	150,4±17,30^∗	156,8±12,4^∗

C: control group; M: group treated with myriocin; D: streptozotocin-induced diabetic group; D + M: streptozotocin-induced diabetic group treated with myriocin; FFA: free fatty acids. Results are based on 8 independent preparations for each experimental treatment (means ± SE).
^∗𝑃<0,01 compared with C group. ^†𝑃<0,01 compared with D group. nd: not detected.